Close Menu

GenomeWebinars

Wed
Sep
30
12:00 pm2020
Sponsored by
LGC SeraCare Life Sciences

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

Genome Webinar

Chief Medical Officer, Bionano Genomics

Clinical Associate Professor, Obstetrics & Gynecology, Maternal Fetal Medicine


Consultant Clinical Scientist
Director of GenQA

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. With a growing number of available assays and more labs offering testing, it is essential to have consistency in reporting and the ability to compare results and validate current or new methods.

This webinar will feature a panel of experts in the field who will provide key insights into the current needs in prenatal testing, the complexities of selecting an assay format and performing quality control, as well as other challenges that labs face when setting up and validating an NIPT assay.

The panelists bring a wealth of expertise and differing viewpoints in clinical laboratory practice, diagnosis of pregnancy complications, and new molecular methods for diagnosis and treatment of pregnancy anomalies and complications. Each speaker will have an opportunity to share their perspectives on this topic, which will be moderated by Dr. Russell Garlick, Chief Scientific Officer at LGC SeraCare. The presentation will be followed by a live Q&A to allow attendees to address the experts directly.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections. The agency's policies for granting EUAs for both molecular and antibody tests evolved over time as more was learned about SARS-CoV-2 and its spread, and diagnostics firms and labs needed to adapt to these changes.

Dr. Elizabeth Hillebrenner, associate director for scientific and regulatory programs at the FDA's Center for Devices and Radiological Health, will kick off this virtual roundtable with an overview of the EUA program, how it evolved, and how lessons learned during the current pandemic may shape future policies and actions by the FDA. She will then take part in a panel discussion that will include a variety of stakeholders from the diagnostics and clinical lab industries. Panelists will include Dr. Robert Boorstein, Medical Director of Lenco Diagnostic Laboratories; Danelle Miller, VP, Global Regulatory Policy and Intelligence for Roche Diagnostics; Dr. Jeffrey Klausner, Professor of Medicine and Public Health at UCLA David Geffen School of Medicine and Fielding School of Public Health; and Gail Javitt, Director at Hyman, Phelps & McNamara.

Sponsored by
Tue
Oct
27
11:00 am2020
Sponsored by
LGC SeraCare Life Sciences

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

Genome Webinar

Professor of Molecular Oncological Pathology,
University of Groningen

Consultant Clinical Scientist and Director,
Genomics Quality Assessment

Scientific Associate
Institute of Pathology, Charité – Universitätsmedizin Berlin

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

The use of circulating tumor DNA (ctDNA) as a surrogate sample type for tumor tissue is an area of significant clinical interest. ctDNA has been demonstrated to mirror the solid tumor mutational landscape and has the potential for early diagnosis of cancer as well as monitoring and tracking biomarkers associated with residual disease over time.

Despite this promise, there are still open questions regarding the best way to implement liquid biopsy approaches in the clinical setting. Our panel brings together academic, clinical, and industry experts in liquid biopsy technologies who will describe the applications of this technique and discuss its benefits and shortcomings in the context of cancer care.

Sponsored by